Register for our free email digests:
University of California, San Francisco
Division of University of California
Latest From University of California, San Francisco
Derived from Strategic Transactions, Informa’s premium source for tracking life-sciences deals, the bi-monthly Pacts In Medtech column pulls up notable technology alliances, R&D partnerships and commercial collaborations. In this edition, we highlight industry pacts that were sealed in March and April 2017.
Jeffrey Patrick joins Ohio State's effort to develop cancer drugs from internal research, bringing a biopharma viewpoint to optimizing such programs before the deal-making effort starts. Plus, the EMA sets a framework for academic interaction, and more tech transfer news.
Expansion of 2015 development partnership adds lung and bladder cancer as well as renal and head-and-neck carcinoma to trials of the two immuno-oncology drugs. Jazz licenses Japanese rights to two of its commercial products to Nippon Shinyaku.
Intellectual property licensed from UCSF focuses on non-mutated, wild-type CFTR activators and inhibitors, thought to offer potential in ophthalmic, renal and gastrointestinal indications.
You must sign in to use this functionality
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.